« Back
Home /
Sapacitabine

Sapacitabine

Item no.	HY-16445-100mg
Manufacturer	MedChem Express
CASRN	151823-14-2
Amount	100 mg
Quantity options	100 mg 10mM/1mL 10 mg 25 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Breast Cancer
Type	Inhibitors
Specific against	other
Purity	98.13
Formula	C26H42N4O5
Citations	[1]Serova M, et al. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells. Br J Cancer. 2007 Sep 3;97(5):628-36.<br/>[2]Green SR, et al. Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types. Br J Cancer. 2010 Oct 26;103(9):1391-9.
Smiles	O=C(N=C(NC(CCCCCCCCCCCCCCC)=O)C=C1)N1[C@H]2[C@@H](C#N)[C@H](O)[C@@H](CO)O2
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CS682; CYC682
Available
Product Description	Sapacitabine is an orally available nucleoside analog proagent that is structurally related to cytarabine.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	490.64
Clinical Information	Phase 3
Manufacturers Research Area	Cancer
Solubility	DMSO : 33.33 mg/mL (ultrasonic)
Target	Nucleoside Antimetabolite/Analog
Manufacturers Target	Nucleoside Antimetabolite/Analog
Manufacturers Pathway	Cell Cycle/DNA Damage
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-16445-100mg-safety-datasheet.pdf